ReviewDrug delivery and translational research2024
Exosome: From biology to drug delivery.
Review in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Research progress on exosomes in the otology field: a systematic review.Stem cell research & therapy · 2025Pooled it
- Exosomes displaying native EGF enhance doxorubicin's therapeutic efficacy and reduce cardiotoxicity.Journal of nanobiotechnology · 2026Article
- Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD.International journal of nanomedicine · 2026Review
- Plant-derived extracellular vesicles for drug delivery: current and future.Regenerative biomaterials · 2026Review
- Plant-Derived Exosome-Like Nanoparticles in Neurodegenerative Diseases: From Dual Bioactive-Delivery Roles to Translational Challenges.International journal of nanomedicine · 2026Review
- Article
- Insights into extracellular vesicle-based platforms on the way to cancer treatment.Journal of translational medicine · 2025Review
- Mesenchymal stem cell-derived exosomes ameliorate gentamicin-induced vestibular hair cell injury by regulating the SNARE pathway and enhancing autophagy.Stem cell research & therapy · 2025Article
- Comparison of production methods for mesenchymal stem cell-derived small extracellular vesicles and evaluation of their effects on retinal pigment epithelium.Scientific reports · 2025Article
- Epimedium-Derived Exosome-Loaded GelMA Hydrogel Enhances MC3T3-E1 Osteogenesis via PI3K/Akt Pathway.Cells · 2025Article
- A New Perspective on Regenerative Medicine: Plant-Derived Extracellular Vesicles.Biomolecules · 2025Review
- Therapeutic Efficacy of Plant-Derived Exosomes for Advanced Scar Treatment: Quantitative Analysis Using Standardized Assessment Scales.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting Decidual CD16Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exosome-based immunotherapy in hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- Exosome technology: A novel and effective drug delivery system in the field of cancer therapy.World journal of gastrointestinal oncology · 2025Article
- Plant-derived extracellular vesicles: a synergetic combination of a drug delivery system and a source of natural bioactive compounds.Drug delivery and translational research · 2025Review
- CAR-exosomes derived from immune cells: an emerging nanoscale vanguard in overcoming tumor immunotherapy hurdles.Frontiers in immunology · 2025Review
- Exosome-mediated miRNA delivery: a molecular switch for reshaping neuropathic pain therapy.Frontiers in molecular neuroscience · 2025Review
- Extracellular vesicles and miRNA-based therapies in triple-negative breast cancer: advances and clinical perspectives.Extracellular vesicles and circulating nucleic acids · 2025Review
- Triple role of exosomes in lung transplantation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, different advancements have been observed in nanosized drug delivery systems. Factors such as stability, safety and targeting efficiency cause hindrances in the clinical translation of these synthetic nanocarriers. Therefore, researchers employed endogenous nanocarriers like exosomes as drug delivery vehicles that have an inherent ability to target more efficiently after appropriate functionalization and show higher biocompatibility and less immunogenicity and facilitate penetration through the biological barriers more quickly than the other available carriers. Exosomes are biologically derived lipid bilayer-enclosed nanosized extracellular vesicles (size ranges from 30 to 150 nm) secreted from both prokaryotic and eukaryotic cells and appears significantly in the extracellular space. These EVs (extracellular vesicles) can exist in different sources, including mammals, plants and microorganisms. Different advanced techniques have been introduced for the isolation of exosomes to overcome the existing barriers present with conventional methods. Extensive research on the application of exosomes in therapeutic delivery for treating various diseases related to central nervous system, bone, cancer, skin, etc. has been employed. Several studies are on different stages of clinical trials, and many exosomes patents have been registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.